HopeStage
Back to all studies
TerminatedNCT00758966

Naltrexone SR and Fluoxetine Combination Therapy in Subjects With OCD

Medication studyAges 18–60United States
The study in practice

Understand this study

Who could participate?

This study is for people with OCD. Listed age limits: 18 years to 60 years. Other eligibility criteria apply.

Listed locations
National City and 10 more locationsSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateSeptember 2008
Recruitment status
Terminated
Enrollment listed in the registry
8
Sponsor
Orexigen Therapeutics, Inc
Sponsor type
Biotech company
Study type
Drug
Intervention type
Drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States
Age range
From 18 Years to 60 Years
Official registry ID
NCT00758966
Official title
Show the full official title

A Proof-of-Concept, Multicenter, Randomized, Double-Blind, Parallel Study of Naltrexone Sustained-Release (SR) and/or Fluoxetine Therapy in the Treatment of Subjects With Obsessive-Compulsive Disorder (OCD)

Recruitment & locations

Terminated

National City · San Diego · Gainesville

8 more locations
  • Atlanta
  • Indianapolis
  • Princeton
  • Brooklyn
  • Cincinnati
  • Portland
  • Columbia
  • Brown Deer

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Orexigen Therapeutics, Inc.

Does this study involve medication?

Yes. The study involves medication, including Fluoxetine 60 mg, Naltrexone 32 mg and fluoxetine 60 mg and Naltrexone SR 32 mg.

Who can participate?

This study is for people with OCD. Listed age limits: 18 years to 60 years. Other eligibility criteria apply.

Is this study still recruiting?

The registry lists this study as terminated.

Want to explore more studies?

Explore studies